Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.34 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513411 | 1.00 | CPN1 (0.46) | CPN1CPB2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3104043 | 0.98 | CPN1 (0.44) | CPN1CPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL17315805 | 0.86 | — | — | |
| SCHEMBL17315807 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL20898681 | 0.85 | SLC6A1 (0.44) | CPN1CPB2GNAI3GNAO1GNAI1 | |
| Trifluoroacetic Acid SCHEMBL29891131 | 0.84 | CPN1 (0.46) | CPN1CPB2SLC6A1GABRA5GABRB2 | |
| SCHEMBL9167927 | 0.82 | TSHR (0.37) | ANPEPAKR1C3TDP1TSHR | |
| SCHEMBL14386678 | 0.82 | — | — | |
| SCHEMBL9819705 | 0.82 | — | — | |
| SCHEMBL26091273 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| US-6455548-B2 | FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-01-31 | — | — | US | disclosed |
| WO-2001064216-A1 | 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| US-4345071-A | AZIDOALKYL-HETEROCYCLIC AMIDINE INTERMEDIATES | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1982-08-17 | — | — | US | disclosed |
| US-4229443-A | Derivatives of penicillanic acid | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | CCR1, CCR4, CCR3 | CPN1 1931/4885CPB2 3021/4885GNAI3 338/4885 |
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | CPN1 3035/4885CPB2 3422/4885GNAI3 70/4885 |
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | CPN1 108/4885CPB2 54/4885GNAI3 1443/4885 |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | CPN1 1825/4885CPB2 2442/4885GNAI3 2665/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | CPN1 108/4885CPB2 54/4885GNAI3 1443/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CPN1 4698/4885CPB2 4514/4885GNAI3 449/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | CPN1 4698/4885CPB2 4514/4885GNAI3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.